Takeda Pharmaceutical Company Limited

Ikuo Fujimori

Masami Yamada

Makoto Kamata

Toshihiro Imaeda

Yasuyoshi Arikawa

Masataka Murakami

Haruyuki Nishida

Kenichiro Shimokawa

Masaki Seto

Takahiro Sugimoto

Shinkichi Suzuki

Masaki Ogino

Jinichi Yonemori

Tomohiro Ohashi

Minoru Nakamura

Hiroki Sakamoto

Hideo Suzuki

Tsuneo Yasuma

Takuto Kojima

Haruhi Ando

Kazuaki Takami

Tomohiro Okawa

Yasutomi Asano

Hironobu Maezaki

Ayumu Sato

Taku Kamei

Zenichi Ikeda

Tohru Yamashita

Shinobu Sasaki

Takeshi Wakabayashi

Tomoya Yukawa

Hideki Hirose

Ryo Mizojiri

Steve Swann

Takuya Fujimoto

Tomoko Ohashi

Yasuhiro Tsukimi

Yuya Oguro

Eiji Kimura

Makoto Fushimi

Nobuki Sakauchi

Tetsuya Tsukamoto

Nobuyuki Matsunaga

Hiroshi Imoto

Asato Kina

Yuji Ishichi

Kazuko Yonemori

Yoshihisa Nakada

Tomoko Ashizawa

Yusuke Ohba

Ryosuke Arai

Kyoko Toyofuku

Takashi Miki

Goushi Nishida

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Nitrogen-containing heterocyclic compound

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a Calkyl group substituted by 1 to 5 halogen atoms; and X is &#x2014;CH&#x2550; or &#x2014;N&#x2550;, or a salt thereof.

The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014; or &#x2014;SO&#x2014;; Ris a Calkyl group optionally having substituent(s) (provided that when L is &#x2014;O&#x2014;, Ris not a Calkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); Xis &#x2014;CRa&#x2550; or &#x2014;N&#x2550;; Xis &#x2014;CRb&#x2550; or &#x2014;N&#x2550;; Xis &#x2014;CRc= or &#x2014;N&#x2550;; Ra, Rb and Rc are each a Calkyl group, Calkenyl group, Calkoxy group, Ccycloalkyl group, Ccycloalkoxy group or Caryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

Bicyclic heterocyclic compound containing a substituted pyrrole ring

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Bicyclic compound

The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R, Rand Rare each a hydrogen atom, a halogen atom, a Calkyl group optionally substituted by halogen or a Calkoxy group optionally substituted by halogen, Rand Rare each a hydrogen atom, a halogen atom or a Calkyl group optionally substituted by halogen, Ris a hydrogen atom, a halogen atom, a Calkyl group optionally substituted by halogen or a Calkoxy group optionally substituted by halogen, and Ris a hydrogen atom or a Calkyl group optionally substituted by halogen or a salt thereof, or a pharmaceutical composition containing the same.

Pyrrole compounds

Provided is a compound having a superior acid secretion suppressive action, antiulcer activity and the like. A compound represented by the formula wherein Ris a substituent, Ris (i) a hydrogen atom, (ii) a Calkyl group optionally having a halogen atom or (iii) a cyano group, Ris (i) a hydrogen atom, (ii) a halogen atom, (iii) a cyano group, (iv) a Calkyl group optionally having a halogen atom or a Calkoxy group optionally having a halogen atom, one of Rand Ris a hydrogen atom, and the other is a substituent other than a hydrogen atom, or a salt thereof.

Pyrazole compound

Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.

Heterocyclic compounds

The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.

Growing community of inventors

Kanagawa, Japan

Ikuo Fujimori